Literature DB >> 16015368

Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.

H-F Dong1, K Wigmore, M N Carrington, M Dean, J A Turpin, O M Z Howard.   

Abstract

CCR5 is one of the primary coreceptors for Env-mediated fusion between cells and human immunodeficiency virus type 1 (HIV-1). Analyses of CCR5 variants in cohorts of HIV-1 high-risk individuals led to the identification of multiple single amino-acid substitutions, which may have functional consequences. This study focused on eight naturally occurring allelic variants located between amino-acid residues 60 and 334 of CCR5. All studied allelic variants were highly expressed on the cell surface of HEK-293 cells and permissive for HIV-1 infection. Variant G301V showed 3.5-fold increase in 50% effective concentration (EC(50)) for CCL4 (MIP 1beta) in a competitive binding assay. There was also a significant reduction in CCL5 (RANTES) EC(50) for the R223Q, A335V and Y339F variants. The most unexpected functional abnormality was exhibited by the R60S variant that exhibited a loss of ligand-induced desensitization in chemotaxis assays, but showed normal CCL4 and CCL5 binding avidity. This mutation is located in the first intracellular loop, a domain that has not previously been shown to be involved in receptor desensitization. In conclusion, our results support earlier studies showing that these naturally occurring point mutations do not limit HIV-1 infection, and indicated that single amino-acid changes can have unexpected functional consequences. Genes and Immunity (2005) 6, 609-619. doi:10.1038/sj.gene.6364247; published online 14 July 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015368      PMCID: PMC1369982          DOI: 10.1038/sj.gene.6364247

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  63 in total

Review 1.  International union of pharmacology. XXII. Nomenclature for chemokine receptors.

Authors:  P M Murphy; M Baggiolini; I F Charo; C A Hébert; R Horuk; K Matsushima; L H Miller; J J Oppenheim; C A Power
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

Review 2.  Chemokines: a new classification system and their role in immunity.

Authors:  A Zlotnik; O Yoshie
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

3.  Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent.

Authors:  Nathalie Signoret; Lindsay Hewlett; Silène Wavre; Annegret Pelchen-Matthews; Martin Oppermann; Mark Marsh
Journal:  Mol Biol Cell       Date:  2004-12-09       Impact factor: 4.138

4.  CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis.

Authors:  F Sellebjerg; H O Madsen; C V Jensen; J Jensen; P Garred
Journal:  J Neuroimmunol       Date:  2000-01-03       Impact factor: 3.478

5.  CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group.

Authors:  L F Barcellos; A M Schito; J B Rimmler; E Vittinghoff; A Shih; R Lincoln; S Callier; M K Elkins; D E Goodkin; J L Haines; M A Pericak-Vance; S L Hauser; J R Oksenberg
Journal:  Immunogenetics       Date:  2000-04       Impact factor: 2.846

6.  Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus.

Authors:  T C Dawson; M A Beck; W A Kuziel; F Henderson; N Maeda
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

7.  Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine.

Authors:  P G Andres; P L Beck; E Mizoguchi; A Mizoguchi; A K Bhan; T Dawson; W A Kuziel; N Maeda; R P MacDermott; D K Podolsky; H C Reinecker
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

8.  The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.

Authors:  Enrique Gonzalez; Hemant Kulkarni; Hector Bolivar; Andrea Mangano; Racquel Sanchez; Gabriel Catano; Robert J Nibbs; Barry I Freedman; Marlon P Quinones; Michael J Bamshad; Krishna K Murthy; Brad H Rovin; William Bradley; Robert A Clark; Stephanie A Anderson; Robert J O'connell; Brian K Agan; Seema S Ahuja; Rosa Bologna; Luisa Sen; Matthew J Dolan; Sunil K Ahuja
Journal:  Science       Date:  2005-01-06       Impact factor: 47.728

9.  Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5.

Authors:  Y C Zang; A K Samanta; J B Halder; J Hong; M V Tejada-Simon; V M Rivera; J Z Zhang
Journal:  Brain       Date:  2000-09       Impact factor: 13.501

10.  N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.

Authors:  D J Chabot; H Chen; D S Dimitrov; C C Broder
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

View more
  3 in total

1.  Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning.

Authors:  Jeremiah D Heredia; Jihye Park; Riley J Brubaker; Steven K Szymanski; Kevin S Gill; Erik Procko
Journal:  J Immunol       Date:  2018-04-20       Impact factor: 5.422

2.  mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5.

Authors:  Ulrike Mock; Rafał Machowicz; Ilona Hauber; Stefan Horn; Pierre Abramowski; Belinda Berdien; Joachim Hauber; Boris Fehse
Journal:  Nucleic Acids Res       Date:  2015-05-11       Impact factor: 16.971

3.  CCL4 enhances preosteoclast migration and its receptor CCR5 downregulation by RANKL promotes osteoclastogenesis.

Authors:  Dabin Lee; Kyung-Ju Shin; Dong Wook Kim; Kyung-Ae Yoon; Young-Jin Choi; Bom Nae Rin Lee; Je-Yoel Cho
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.